Ongoing Assessments & Recent Research.
Easy access to our work
Myelodysplastic Syndrome
Jul 2024Paroxysmal Nocturnal Hemoglobinuria
Feb 2024Post-Traumatic Stress Disorder
May 2024Schizophrenia
Feb 2024Featured News & Insights.
Learn about our latest work.
ICER Releases Draft Evidence Report on Treatment for Post-Traumatic Stress Disorder
Public comment period now open until April 22, 2024; Requests to make oral comment during public meeting also being accepted.
03/26/2024Institute for Clinical and Economic Review Publishes Final Evidence Report on Treatments for Paroxysmal Nocturnal Hemoglobinuria
Independent appraisal committee voted that current evidence is not adequate to demonstrate a net health benefit for iptacopan over C5 inhibitor; committee voted that the evidence is adequate to demonstrate a net health benefit for add-on danicopan compared to C5 inhibitor alone
03/13/2024Institute for Clinical and Economic Review Names Henry Claypool to Governance Board
Experienced policy leader with expertise in disability rights and policy, advocacy, academia, and industry will help guide ICER in its mission to work towards a health system where everyone benefits from fair pricing, fair access, and future innovation
03/12/2024Our Origin Story.
Dr. Steve Pearson explains why he founded an organization to advance the use of evidence to improve health care affordability and access for all patients and their families.
The ICER Impact.
New York Medicaid pursued discounts, many of which were in line with ICER reports, which have saved the state over $500 million
Engaged with over 400 patient groups and patient reps
In a landmark international program, HTA agencies around the world can now access ICER’s customizable COVID-19 Cost-Effectiveness Model
Key
Developments.
In 2021, we celebrated our 15th anniversary! Learn more.
In early 2024, NICE announced a collaboration with ICER, CADTH, and ZIN (also known as the National Healthcare Institute in the Netherlands) to share learnings about the development of economic models at the disease level (rather than product level). Learn more about the initiative here.
Listen to our podcast, “A Prescription for Fair Pricing“. Subscribe now on Apple, Google, or Spotify.
Current
Policy Papers.
Easy access to our latest policy papers
Barriers to Fair Access
ICER’s third annual “Barriers to Fair Access” assessment of prescription drug coverage policies within US commercial insurance, and the Veterans Health Administration. The analysis found that major payer coverage policies for 18 drugs often met fair access criteria for cost sharing, clinical eligibility, step therapy, and provider restrictions.
However, the report’s findings suggest that major improvements are needed in the transparency of coverage policy information for consumers, and in detailing out-of-pocket costs for patients.
Unsupported Price Increases
Of 10 high-expenditure drugs that had substantial 2022 net price increases, eight were not supported by new clinical evidence; these increases accounted for $1.27 billion in additional costs over one year.
Additionally, one of three Medicare Part B drugs with high list price increases in 2021 lacked adequate supporting new evidence, directly raising annual out-of-pocket expenses for Medicare patients by up to $680 per year
Evaluating and Advancing Health Technology Assessment Methods that Support Health Equity
ICER received a new grant from The Commonwealth Fund to evaluate procedural and methodological changes that could further support health equity goals in health technology assessment (HTA). The findings from this effort will guide ICER’s update to its value assessment framework and inform the work of other HTA groups worldwide.